TY - JOUR
T1 - Establishment of a quantitative assay of abnormal glycolipid expression in endometrial cells, and its diagnostic value for endometrial carcinoma
AU - Kobayashi, Yoichi
AU - Tsukazaki, Katsumi
AU - Kubushiro, Kaneyuki
AU - Sakayori, Motoko
AU - Nozawa, Shiro
PY - 1996/4/1
Y1 - 1996/4/1
N2 - We developed a new quantitative method for detecting abnormal glycolipid expression in endometrial cells using a monoclonal antibody (MSN-1) and analyzed the glycolipid antigen recognized by MSN-1 in 173 clinical endometrial cell samples (66 normal endometria, 39 endometrial hyperplasias, and 68 endometrial adenocarcinomas). The mean glycolipid antigen levels in normal endometrium, endometrial hyperplasia, and endometrial carcinoma were 0.42 ± 137, 2.13 ± 3.84, and 19.4 ± 25.8 (mean ± SD) units, respectively. If the cutoff rate of this assay was fixed at 1.8 units, the positivity rates for patients with normal endometrium, endometrial hyperplasia, and endometrial carcinoma were 6.1% (4/66). 28.2% (11/39), and 76.5% (52/68), respectively. In 35 endometrial carcinoma patients, endometrial smears were simultaneously performed, and there were 22 positive smears (62.9%). When the cytological diagnosis was combined with our assay, 943% (33/35) of the carcinomas were detected. Thus, this assay seems to be a supplementary diagnostic method for endometrial carcinoma.
AB - We developed a new quantitative method for detecting abnormal glycolipid expression in endometrial cells using a monoclonal antibody (MSN-1) and analyzed the glycolipid antigen recognized by MSN-1 in 173 clinical endometrial cell samples (66 normal endometria, 39 endometrial hyperplasias, and 68 endometrial adenocarcinomas). The mean glycolipid antigen levels in normal endometrium, endometrial hyperplasia, and endometrial carcinoma were 0.42 ± 137, 2.13 ± 3.84, and 19.4 ± 25.8 (mean ± SD) units, respectively. If the cutoff rate of this assay was fixed at 1.8 units, the positivity rates for patients with normal endometrium, endometrial hyperplasia, and endometrial carcinoma were 6.1% (4/66). 28.2% (11/39), and 76.5% (52/68), respectively. In 35 endometrial carcinoma patients, endometrial smears were simultaneously performed, and there were 22 positive smears (62.9%). When the cytological diagnosis was combined with our assay, 943% (33/35) of the carcinomas were detected. Thus, this assay seems to be a supplementary diagnostic method for endometrial carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=0029999053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029999053&partnerID=8YFLogxK
M3 - Article
C2 - 9816226
AN - SCOPUS:0029999053
SN - 1078-0432
VL - 2
SP - 749
EP - 754
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 4
ER -
